Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PARG | Q86W56 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521508 | 0.81 | L3MBTL1 (0.49) | MAPTSMN1; SMN2KDM4EMEN1LMNA | |
| SCHEMBL29952899 | 0.81 | L3MBTL1 (0.49) | MAPTSMN1; SMN2KDM4EMEN1LMNA | |
| SCHEMBL2323303 | 0.81 | ENPP2 (0.55) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL30855790 | 0.79 | KMT2A (0.69) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL17996181 | 0.79 | KMT2A (0.69) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL7140953 | 0.79 | KMT2A (0.74) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL27435146 | 0.79 | SMN1; SMN2 (0.74) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| Boric Acid SCHEMBL5885888 | 0.79 | MAPT (0.58) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL10016535 | 0.79 | SMN1; SMN2 (1.00) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL12804923 | 0.78 | ALDH1A1 (0.48) | MAPTSMN1; SMN2KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104079-A1 | SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-05-22 | — | — | WO | disclosed |
| US-20250066308-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2025-02-27 | — | — | US | disclosed |
| CN-118339145-A | Bicyclic fused ring derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-07-12 | — | — | CN | disclosed |
| EP-4397655-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023055124-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사유한양행 | 2023-04-06 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-2964635-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-05-02 | — | — | EP | disclosed |
| WO-2009040289-A2 | BIARYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-20090088459-A1 | NOVEL BIARYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| US-7511033-B2 | Dihydro-benzo[B][1,4]diazepin-2-one sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMAN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008128889-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261957-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008119689-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066308-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LOX, XDH, IL4I1 | MAPT 4327/4885SMN1; SMN2 4312/4885KDM4E 359/4885 |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | MAPT 658/4885SMN1; SMN2 980/4885KDM4E 2568/4885 |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | MAPT 1103/4885SMN1; SMN2 799/4885KDM4E 1739/4885 |
| US-20080261957-A1 | DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, CNR1 | MAPT 1125/4885SMN1; SMN2 277/4885KDM4E 1453/4885 |
| US-20090088459-A1 | NOVEL BIARYL SULFONAMIDE DERIVATIVES | NR1H3, NR1H2, NR1H4 | MAPT 4604/4885SMN1; SMN2 4569/4885KDM4E 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.